Journal of Oncology

Successes and Challenges for Diagnosis and Therapy of Acute Leukemia


Publishing date
01 Nov 2019
Status
Published
Submission deadline
28 Jun 2019

1University of Bologna, Bologna, Italy

2St. Jude Children’s Research Hospital, Memphis, USA


Successes and Challenges for Diagnosis and Therapy of Acute Leukemia

Description

Acute leukemia is a malignant disease of the blood and bone marrow. It arises from a defect in white blood cells within the bone marrow, which divide out of control, causing proliferation of immature and nonfunctional cells that are subsequently released into the bloodstream and impair all other blood cells.

Acute Leukemia is categorized based on whether the abnormal blast cells have lymphoid or myeloid origin. Acute Lymphoblastic Leukemia (ALL) is the most common childhood malignancy, whereas Acute Myeloid Leukemia (AML) mostly affects older adults and children before the age of 2 years.

Treatment and prognosis depend upon the type of leukemia, severity, and symptoms. In general, the standard treatment options include chemotherapy, radiation therapy, and stem cell transplant. Current treatments allow 5-year overall survival rates of about 60% and 90% in children and 30-40% in adults, for AML and ALL, respectively. However, the high incidence of refractory or relapsed disease in both children and adults still remains a great challenge. In recent years, leukemia therapy has been undergoing profound and incessant changes, due to the introduction of targeted therapies, consisting of molecules against genetic or epigenetic targets in the cancer cells, and immunotherapy, including chimeric antigen receptors (CARs) targeting cell surface markers or monoclonal antibodies.

The development of next generation sequencing (NGS) technologies has revolutionized the ability to examine cancer cells and to identify genomic mutations and structural alterations with extraordinary detail. This has changed leukemia classification, diagnosis, and therapy profoundly. Indeed, recent studies have described novel molecularly distinct leukemia subtypes, for instance, BCR-ABL1-like, ERG/DUX4-, ZNF384-, and MEF2D-rearranged leukemias. Importantly, some of these leukemia subtypes have a clear potential for novel therapeutic intervention. Furthermore, genomic profiling has improved our understanding of the mechanisms responsible for leukemia onset and relapse. To this regard, the identification of genetic mutations that occur before birth and influence the susceptibility to childhood leukemias is considerable. These advances in the genomics of acute leukemia also open new therapeutic options, including immunotherapy and novel targeted molecules, which can be employed as single agents or in combination with conventional chemotherapy, to tailor less detrimental treatments.

Therefore, the major aim of this special issue is to discuss how recent studies have impacted our knowledge of the biology of acute leukemia and the consequent revolution of leukemia management, including diagnosis and treatment challenges. We invite review articles that describe advancement in both ALL and AML management as a result of the identification of novel leukemia subtypes and treatment options and original research papers focused on various aspects of the above-mentioned area.

Potential topics include but are not limited to the following:

  • Novel Leukemia subtypes: consequences for disease classification and clinical management
  • Novel genetic alterations in acute leukemia as potential targets and biomarkers for disease monitoring
  • Genetic susceptibility to leukemia: which are the key players?
  • Advances in understanding the mechanisms of leukemia relapse
  • Novel treatment options to fight acute leukemia: immunotherapy or targeted therapies?

Articles

  • Special Issue
  • - Volume 2019
  • - Article ID 3408318
  • - Editorial

Successes and Challenges for Diagnosis and Therapy of Acute Leukemia

Annalisa Lonetti | Ilaria Iacobucci | Riccardo Masetti
  • Special Issue
  • - Volume 2019
  • - Article ID 5985923
  • - Research Article

Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia

Samantha Bruno | Maria Teresa Bochicchio | ... | Giovanni Martinelli
  • Special Issue
  • - Volume 2019
  • - Article ID 8941471
  • - Review Article

The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukaemia: Challenges for Diagnosis and Therapy

Carle Grobbelaar | Anthony M. Ford
  • Special Issue
  • - Volume 2019
  • - Article ID 8150967
  • - Review Article

Casein and Peptides Derived from Casein as Antileukaemic Agents

Edgar Ledesma-Martínez | Itzen Aguíñiga-Sánchez | ... | Edelmiro Santiago-Osorio
  • Special Issue
  • - Volume 2019
  • - Article ID 8323592
  • - Review Article

Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment

Paolo Bernasconi | Oscar Borsani
  • Special Issue
  • - Volume 2019
  • - Article ID 1609128
  • - Research Article

Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia

Naghmeh Niktoreh | Christiane Walter | ... | Dirk Reinhardt
  • Special Issue
  • - Volume 2019
  • - Article ID 7239206
  • - Review Article

Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies

Luiza Handschuh
  • Special Issue
  • - Volume 2019
  • - Article ID 6179573
  • - Research Article

HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia

Aida Vitkevičienė | Giedrė Skiauterytė | ... | Rūta Navakauskienė
  • Special Issue
  • - Volume 2019
  • - Article ID 4047617
  • - Research Article

Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients

Diana M. Byrnes | Fernando Vargas | ... | Jonathan H. Schatz
Journal of Oncology
 Journal metrics
Acceptance rate28%
Submission to final decision96 days
Acceptance to publication50 days
CiteScore3.220
Impact Factor2.600
 Submit

You are browsing a BETA version of Hindawi.com. Click here to switch back to the original design.